



3 March 2025

## RESPIRI SECURES A\$4 MILLION THROUGH PLACEMENT AND PROPOSES COMPANY NAME CHANGE TO BETTER REFLECT THE NEW BUSINESS MODEL

### Highlights

- Respiri receives firm commitments to raise approximately A\$4 million via a Placement
- Funds raised will support investments in the business to execute on recent and expected customer wins
- The proposed name change to Vitasora Health Limited (**Vitasora**) reflects the organisation's evolution into a full-service **Care Management Company**.
- "**Vitasora**" represents the Company's commitment to patient-centric care, improving and sustaining health, and to solutions that enhance patient outcomes, reduce costs, and drive value-based **Care Beyond the Clinic**.

**Respiri Limited** (ASX:RSH; OTCQB:RSHUF) ("**Respiri**"), a Connected Care Management Company providing remote patient monitoring ("**RPM**") services on behalf of healthcare providers and organisations to patients in the USA, is pleased to announce it has received firm commitments for a capital raising of **A\$4 million** via a placement ("**Placement**") of fully paid ordinary shares ("**New Shares**") to institutional, sophisticated and professional shareholders. The Placement to investors will settle in two tranches, the first tranche of A\$2.7 million ("**First Tranche**") will be issued on or about 10 March 2025 and the second tranche of A\$1.3 million will be issued on or about 5 June 2025 ("**Second Tranche**").

### Placement

The Placement follows the recent completion of the acquisition of the business of Orb Health, Inc. and recent new customer Medicare Shared Savings Plan (MSSP) partnerships that further underpins investor confidence in Respiration's strategy for the U.S. healthcare market and the Company's accelerated commercialisation and execution capabilities.

Chief Executive Officer, Marjan Mikel said:

"We are pleased with the strong support we received from existing and new investors for the Placement. Respiration is experiencing strong demand as demonstrated by recent commercial wins and the substantial sales pipeline of significant clients."

The funds raised will provide essential growth capital to support the acceleration in commercialisation in the U.S. market."

Under the terms of the Placement, the Company will issue 100,000,000 New Shares at an issue price of \$0.04 per New Share. This issue price represents a discount of 16.7% to the Company's last closing price of \$0.048 on Wednesday 26 February 2025. It is intended that 67,481,250 New Shares under the First Tranche (**Tranche 1**) will be issued on or about 10 March 2025 and 32,518,750 New Shares under the Second Tranche (**Tranche 2**) will be issued on or around 5 June 2025, with both Tranche 1 and Tranche 2 utilising the Company's existing Placement Capacity under ASX Listing Rule 7.1. A subscription by Directors will be issued following shareholder approval being sought at the next general meeting of shareholders.

The New Shares will rank equally with existing Respiration fully paid ordinary shares.

Further details are set out in the Appendix 3B released to the ASX on or about the same time as this announcement.



The funds raised from the Placement will enable Respiri to scale its clinical Care Coordinator, sales and account management teams to cater for the existing and expected growth in Accountable Care Organisations (“ACO”), Independent Physician Associations (“IPA”) and other Healthcare Organisation customers. Respiri will also make investments in technology, marketing and customer engagement, in addition to general working capital and capital raising costs.

MST Financial Services Pty Ltd (“MST”) acted as sole manager to the Placement.

### Proposed Change of Company Name

The Company is pleased to announce its intention to change the Company’s name to Vitasora Health Limited (“Vitasora”). A special resolution to approve the name change will be put to shareholders at an Extraordinary General Meeting of Shareholders to be called in the coming months (“EGM”). If approved at the EGM, the name change will be effective from the date that ASIC updates its register to reflect the new name and the associated corporate branding changes will also become effective from that time. “ASX:VHL” has been reserved as the proposed ASX code should the name change be approved.

Respiri has evolved from a respiratory-focused connected care company into a full-service Care Management leader, now rebranded as Vitasora. Our transformation began with the FDA-approved wheezo© device, which provided a strong foundation for our entry into the U.S. market. Through strategic acquisitions, expanding clinical capabilities, and advanced data-driven solutions, we are now at the forefront of comprehensive chronic disease care management across multiple conditions.

With major new ACOs, IPAs and other Healthcare Organisations partnering with us, Vitasora is poised for significant growth in both the traditional fee-or-service and value-based/risk-share agreements, aligning with the broader U.S. healthcare shift toward value-based care, efficiency, and improved patient outcomes. The new U.S. administration’s focus on care management and cost efficiency, together with the Centers for Medicare & Medicaid Services (“CMS”) mandate supporting a shift in this direction and the American Medical Association’s endorsement of RPM as a key component in tackling chronic diseases, further strengthens our position as a trusted partner for healthcare providers and payers.

Vitasora’s bespoke Care Management model empowers healthcare organisations to extend care beyond their clinics seamlessly, integrating multi-device remote monitoring, virtual clinical support and AI-powered decision-making. This approach not only improves patient engagement and compliance but also enhances health outcomes while reducing overall system costs.

Our new name reflects our mission and vision:

- “Vita” (Latin for life): A commitment to sustaining and improving patient health.
- “Sora” (Japanese for sky): Limitless possibilities in transforming healthcare delivery.

As Vitasora, we continue setting new standards for scalable, high-impact connected care, ensuring that healthcare providers, payers, and Healthcare Organisations achieve better patient outcomes while driving sustainable financial success by providing “Care Beyond the Clinic”.



For further information, investors and media please contact:

**Mr Marjan Mikel**

CEO & Managing Director

Respiri Limited

P: +61 408 462 873

E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**

Chairman

Respiri Limited

P: +61 447 074 160

E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.*

---

## About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at [www.respiri.co/au](http://www.respiri.co/au)

## About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions



shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.